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Background: Hairy and enhancer of split 1 (HES1), a basic helix-loop-helix transcriptional repressor, is a downstream
target of Notch signaling. Notch signaling and HES1 expression have been linked to growth and survival in a
variety of human cancer types and have been associated with increased metastasis and invasiveness in human
osteosarcoma cell lines. Osteosarcoma (OSA) is an aggressive cancer demonstrating both high metastatic rate and
chemotherapeutic resistance. The current study examined expression of Notch signaling mediators in primary
canine OSA tumors and canine and human osteosarcoma cell lines to assess their role in OSA development and
progression.
Results: Reverse transcriptase - quantitative PCR (RT-qPCR) was utilized to quantify HES1, HEY1, NOTCH1 and
NOTCH2 gene expression in matched tumor and normal metaphyseal bone samples taken from dogs treated for
appendicular OSA at the Colorado State University Veterinary Teaching Hospital. Gene expression was also assessed
in tumors from dogs with a disease free interval (DFI) of <100 days compared to those with a DFI > 300 days
following treatment with surgical amputation followed by standard chemotherapy. Immunohistochemistry was
performed to confirm expression of HES1. Data from RT-qPCR and immunohistochemical (IHC) experiments were
analyzed using REST2009 software and survival analysis based on IHC expression employed the Kaplan-Meier
method and log rank analysis. Unbiased clustered images were generated from gene array analysis data for Notch/
HES1 associated genes.
Gene array analysis of Notch/HES1 associated genes suggested alterations in the Notch signaling pathway may
contribute to the development of canine OSA. HES1 mRNA expression was elevated in tumor samples relative to
normal bone, but decreased in tumor samples from dogs with a DFI < 100 days relative to those with a DFI >
300 days. NOTCH2 and HEY1 mRNA expression was also elevated in tumors relative to normal bone, but was not
differentially expressed between the DFI tumor groups. Survival analysis confirmed an association between
decreased HES1 immunosignal and shorter DFI.
Conclusions: Our findings suggest that activation of Notch signaling occurs and may contribute to the
development of canine OSA. However, association of low HES1 expression and shorter DFI suggests that
mechanisms that do not alter HES1 expression may drive the most aggressive tumors.
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Osteosarcoma (OSA) is the most common malignant
bone tumor among children and adolescents with an in-
cidence of 4.4 cases per million per year in the United
States [1]. OSA is also the most common spontaneous
primary bone tumor of dogs, estimated to affect greater
than 8,000 dogs annually in the United States [2].
Tumor morphology, biological behavior, progression of
disease and molecular characteristics are very similar in
dogs and humans [2-7]. Consequently, dogs provide a
valuable comparative model of human OSA. Standard
of care therapy for both human and canine OSA pa-
tients remains a combination of surgery and chemother-
apy, with five-year survival rates reported in humans as
high as 70% [1,8] and median survival in canine patients
around 200 days [2]. Unfortunately, in both human and
canine patients approximately 80% are estimated to
have micrometastases at presentation, some of whose
tumors are also refractory to chemotherapy [2,8]. These
patients continue to have a poor prognosis. Histologic
classification alone has not proven clinically relevant for
determination of tumors likely to metastasize or exhibit
resistance to chemotherapy protocols. The focus of re-
cent research, therefore, has turned toward molecular
characterization of primary tumors, especially aberrant
gene and/or protein expression that might correlate
with prognosis or chemotherapy sensitivity.
Hairy and enhancer of split 1 (HES1), a basic helix-loop-
helix (bHLH) transcriptional repressor, is a downstream
target of the Notch signaling pathway. The intracellular
domain of activated Notch receptors (NICD) translocates
to the nucleus, forms a transcriptional activating complex
with recombination signal binding protein for immuno-
globulin kappa J region (RPBJκ) and activates expression
of target genes including HES1 [9,10]. The HES1 protein
contains both DNA-binding and protein-protein inter-
action domains important for its function as a transcrip-
tional regulator (including negative regulation of its own
transcription) [9,11,12]. Notch-independent HES1 expres-
sion can also result from Hedgehog and c-Jun N-terminal
kinase (JNK) signaling as well as from RAS/MAPK signal-
ing [10,13-15]. Regulation of HES1 expression and activity
is dependent on the tissue, spatial and temporal factors,
and the proteins with which it interacts [9,10].
Overexpression of Notch and/or HES1 is associated
with a variety of human cancers including T-cell acute
lymphoblastic leukemia (ALL), and ovarian, breast, cer-
vical, prostate, colon and non-small cell lung cancers
[16-19]. Notch/HES1 has also been shown to have tumor
suppressor activity in some cancers including hepatocellu-
lar carcinoma, B-cell ALL, myeloid leukemia and neuro-
blastoma [20-23]. In human OSA, Notch is implicated in
OSA cell proliferation, invasion and metastasis [24,25]. In-
creased HES1 mRNA expression was shown in somehuman OSA cells and OSA tumor samples compared to
osteoblasts or normal bone and an association between
high HES1 expression and decreased survival of OSA
patients has been suggested [24-27]. Reduced invasive-
ness in response to suppression of Notch signaling and
HES1 activity implicates Notch/HES1 signaling in me-
tastasis [28]. Another study suggests both up-regulation
of Notch and increased expression of HES1 in one OSA
cell line occurs in response to activation of the Wnt/β-
catenin pathway [29].
During bone development there is significant cross
talk between the Wnt/β-catenin, hedgehog, and Notch
pathways affecting osteoblast differentiation and mat-
uration and influencing HES1 expression [10,29-31].
Like Notch and Wnt/β-catenin, aberrant hedgehog sig-
naling is also associated with development of human
cancers [31]. Previous studies in our lab identified
decreased expression of three hedgehog pathway asso-
ciated genes in OSA tumors from dogs with a disease
free interval (DFI) < 100 days (poor-responders) com-
pared with tumors from dogs with a DFI > 300 (good-
responders) [32].
In order to explore the hypothesis that Notch signaling
would be altered in canine OSA compared to normal
bone samples, the current study examines the expression
of NOTCH1 and 2 receptors and signaling targets,
HES1 and HEY1, in canine OSA samples from patients
with known outcome and normal bone tissues. Immuno-
histochemical analysis of HES1 protein was assessed in
Kaplan-Meyer survival analysis to confirm the associ-
ation of decreased HES1 expression with a shorter DFI.
Methods
Tumor donors
Chemotherapy-naïve primary tumor samples were se-
lected from the Colorado State University (CSU) Flint
Animal Cancer Center’s tissue archive. Samples are ar-
chived with owner consent and approval by the CSU
Institutional Animal Care and Use Committee. Twenty
tumors from good- and poor-responders (n = 10 each
group) were selected following the protocol previously
published [32]. Briefly, chemotherapy-naïve primary OSA
samples were from dogs treated with surgical amputation
followed by chemotherapy with doxorubicin and/or a plat-
inum based drug (distribution of choice of drug was not
significantly different between groups). All twenty dogs
were free of thoracic metastases by radiographic analysis
at diagnosis and follow up consisted of evaluation by clin-
ical examinations including thoracic radiographs every 2–
3 months after initial treatment. Disease free interval
(DFI) was calculated from surgery until development of
metastatic disease and samples were identified for cohorts
of good responders (DFI > 300 days) and poor responders
(DFI < 100 days) in order to flank the median DFI
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samples were collected from which matched normal
metaphyseal bone was harvested from the same limb (at
least one joint space away from the tumor) following am-
putation. These nine matched samples were collected at
amputation as cases came in (convenience sample) and
absence/presence of metastasis, post-operative treatment,
and patient follow-up were less consistent in this popula-
tion. Tumor and normal bone fragments collected at
amputation were flash-frozen in liquid nitrogen and stored
at -80°C. Tumor fragments were also fixed in 10% neutral
buffered formalin for 24 hours with subsequent routine
processing and paraffin embedding.
Immunohistochemical HES1 expression was also assessed
in a subset of canine appendicular OSA patients from
a previously reported multi-institutional randomized pro-
spective clinical trial [33]. The study was approved by
the Institutional Animal Care and Use Committees of
the participating institutions. All dogs underwent am-
putation followed by 5 cycles of adjuvant doxorubicin,
with or without an investigational matrix metallopro-
tease inhibitor. Inclusion/exclusion criteria, staging, and
follow-up procedures were standardized and tumor
tissues were processed as previously reported [33]. Histo-
logic grading (from 1 to 3) was performed by one author
(BEP) utilizing a schema incorporating amount of matrix,
percent necrosis, nuclear pleomorphism, nucleolar size/
number and mitosis score [33]. Mitotic index was calcu-
lated by counting the number of mitotic figures per 10
random 400× fields.
Cell culture
Canine cell lines used in this study were provided by Dr.
Douglas Thamm; all cell lines were validated for species
and genetic identity using short-tandem-repeat (STR) pro-
filing as previously described [34]. Human OSA cell lines
were obtained from Dr. Douglas Thamm (MG63, SAOS-2,
SJSA-1), Dr. Hue Luu (MG63.2), or purchased from ATCC
(U2OS). The MG63.2 cell line is a metastatic sub-line of
the MG63 line, obtained via serial passage of rare lung me-
tastases from MG63 [35]. All non-purchased cell lines were
validated prior to use using STR profiling by the University
of Colorado DNA Sequencing Shared Resource. Cells were
cultured in C10 media (DMEM high glucose with 4 mM
L-glutamine (Hyclone Laboratories, Inc.), 1 mM of sodium
pyruvate, 2× MEM vitamins, 1× MEM non-essential amino
acids, 1× antibiotic-antimycotic (100×: 10,000 IU/ml peni-
cillin, 10,000 ug/ul streptomycin and 25ug/ml) (all additives
from Mediatech, Inc.), and 10% fetal bovine serum (FBS)
(Atlas Biologicals, Fort Collins, CO).
RNA extraction
Total RNA was extracted from tumors and RT-qPCR
was conducted as described previously [32]. Briefly,samples were freeze-fractured, homogenized, extracted
with Trizol reagent (Invitrogen, Carlsbad, CA) and puri-
fied with RNeasy clean up (Quiagen, Valencia, CA) fol-
lowing manufacturer’s protocols. RNA was extracted
from normal bone using the same protocol with an add-
itional spin of 800× g at 4°C for 5 minutes following
homogenization. The supernatant was carried forward
through the Trizol protocol. Total RNA was extracted
from human and canine OSA cells using the RNeasy Kit
(Qiagen) per the manufacturer’s protocol. RNA was
quantified via spectrophotometry and bioanalyzed for in-
tegrity as described in O’Donaghue et al. [32] with sam-
ples used having a RNA integrity number of at least 8.
Human adult osteoblast total RNA was purchased from
CELL Applications, Inc.
Reverse transcriptase PCR and quantitative real time PCR
cDNA synthesis was completed using the QuantiTect Re-
verse Transcription Kit (Qiagen) with 1 or 3 μg input RNA.
RT-qPCR of cDNA was run using iQ SYBR Green
Supermix (Bio-Rad) and 25 ng equivalent RNA input in
25 μL reactions on a Stratagene Mx3000P instrument.
Expression in canine cells and tissues was normalized to
hypoxanthine phosphoribosyltransferase 1 (HPRT1) expres-
sion. HPRT1 was selected based on its consistent moderate
expression in our sample sets in prior microarray and RT-
qPCR analysis (see Additional file 1 and reference [32]) and
its previous use as a canine reference gene [36]. Consistent
with current recommendations for the selection of refer-
ence genes and because no single reference gene exhibited
unchanged expression between samples, expression in hu-
man OSA cells was normalized to the geometric mean of
four reference genes; ribosomal protein S15 (RBS15),
glyceraldehyde-3-dehydrogenase (GAPDH), 18S ribosomal
RNA (18SrRNA) and HPRT1 [37]. Primer sequences and
efficiencies for all genes and the full sequence of the canine
HES1 amplicon are listed in Additional file 2. Primers were
designed using Primer-Blast based upon NCBI RefSeq
mRNA sequences when available. Primers were designed to
be intron spanning when possible and cross-checked for
specificity via UCSC in silico PCR. Primers were further
validated with standard curves to calculate efficiency, and
dissociation curves as previously described [34]. RT-qPCR
products were validated for size by agarose gel electrophor-
esis and sequenced to confirm identity. The 161 bp canine
HES1 amplicon revealed 98% homology to the human
homolog of HES1. Human HES1 primers used were the
same as those used by Zhang et al. [24]. The identity of the
200 bp amplicon was verified as human HES1 by dideoxy
sequencing (CSU DNA sequencing Core).
Western blot
Western blot analysis was performed on canine and hu-
man OSA cells using whole cell lysates or cytoplasmic
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in triethanolamine (TEA) lysis buffer (55 mM TEA,
pH 7.5, 111 mM NaCl, and 2.2 mM EDTA, 0.44% SDS)
with 1× Complete Protease Inhibitor Cocktail (Roche
Diagnostics). Protein concentrations were determined
using the bicinchoninic acid (BCA) protein assay
(Thermo Scientific). Nuclear extracts were prepared
using a hypotonic 0.5% or 0.25% IgePal (NP-40) buffer
(10 mM Hepes, 1.5 mM MgCl, and 10 mM KCl). Briefly,
harvested cell pellets were re-suspended in IgePal buffer
with protease inhibitor while vortexing, incubated on
ice for 0–5 minutes, and centrifuged for 5 minutes at
500× g. The supernatant (cytoplasmic fraction) was
collected and the pellet (nuclear fraction) was re-
suspended in TEA lysis buffer with protease inhibitors.
Samples were separated using SDS-PAGE and trans-
ferred to a polyvinylidine fluoride membrane. The
membrane was blocked with 5% non-fat dry milk
(NFDM) for one hour at room temperature and incu-
bated with rabbit monoclonal anti-HES1 antibody
(RabMAb EPR4226, 1:500; Epitomics) in 5% bovine
serum albumin (BSA) at 4°C overnight. After washing in
0.1% Tween 20-Tris-buffered saline (TBST) the mem-
brane was incubated with secondary horseradish per-
oxidase conjugated goat anti-rabbit antibody (1:5000;
Bio-Rad) in 5% NFDM for one hour at room tem-
perature. SuperSignal West Dura Extended Duration
Substrate (Pierce Biotechnology) was used to detect
chemiluminescent signals. Band intensity from four ex-
periments using whole cell lysates from MG63 and
MG63.2 cell lines were analyzed using ImageJ software.
The intensity of the HES1 band was normalized to the
corresponding α-tubulin loading control.
Immunohistochemistry (IHC)
IHC to detect HES1 expression was performed on 4 μm
sections from formalin-fixed paraffin embedded (FFPE)
tumor tissues using standard immunoperoxidase tech-
niques on charged slides with hematoxylin counter stain.
Slides with sections were heated at 60°C for 30 minutes,
allowed to cool, and deparaffinized with xylene or a citrus
based clearing solution (Thermo-Fisher Scientific), and
rehydrated with descending ethanol concentrations in de-
ionized water (100%, 95%, 75% and 50%). Heat induced
epitope retrieval was done with 10 mM sodium citrate
buffer (pH 6.0) heated in a pressure cooker for 1 minute
at 125°C. Endogenous peroxidase activity was blocked
with 3% hydrogen peroxide at room temperature for 5 mi-
nutes with 3 washes in TBST both before and after. Slides
were incubated with a non-serum protein block (Back-
ground Sniper, Biocare Medical) at room temperature for
15 minutes followed by incubation with primary antibody
overnight at 4°C overnight. The primary antibody (anti-
HES1 RabMAb, Epitomics) was used at a dilution of 1:750(diluted in Antibody Diluent, Dako). Sections were then in-
cubated with a prediluted secondary antibody conjugated
to horseradish peroxidase (Envision and Dual Link System
HRP, Dako) for 30 minutes at room temperature with 3
TBST washes both before and after. Diaminobenzidine
(DAB, Ventana Medical Systems) was used as a chromogen
for immunoreactive complex detection and slides were
counterstained with hematoxylin.
Sixty-one additional FFPE tumor samples were ana-
lyzed for HES1 immunohistochemical expression utiliz-
ing a protocol similar to that described above with the
following exceptions: primary antibody was diluted in
2.5% normal goat serum in TBST (1:750 or 1:375, higher
antibody concentration was used in subsequent batches
to increase immunoreactivity signal), and detection was
performed using biotinylated anti-rabbit IgG antibody in
a Vectastain ABC Kit (Vector Laboratories). The IHC
was performed in five batches of 8 to 18 slides each with
the same antibody dilution used for an entire batch. Var-
iations in antibody dilutions were controlled for by in-
clusion of a positive control tumor slide with a total
immunoreactivity score of 4 (percent cells staining score
of 2 and intensity score of 2; Table 1). All samples within
each batch were scored in reference to the control.
Negative controls lacking primary antibody were in-
cluded in each batch.
HES1 antibody validation was done using human pla-
centa and canine lung and pancreas as positive control
tissues. Specificity of the primary antibody was verified
using a HES1 blocking peptide (Epitomics). Briefly,
primary antibody was incubated with 25× (by mass)
blocking peptide in antibody diluents (at both 1:375 and
1:750) for one hour at room temperature before applica-
tion to canine control and sample tumor slides. Positive
and negative controls with sections from the same tis-
sues were incubated in parallel.
Immunohistochemical scoring of all slides was per-
formed independently by two authors blinded to case in-
formation. A positive cell was any neoplastic cell with
distinct brown staining in the nucleus (stromal cells and
endothelial cells were not counted). The percentage of
positive cells in each sample was estimated based on an
average of two or more high powered fields and scored
as follows, 1: < 50% cells stain positive, 2: 50-75% cells
stain positive, 3: > 75% cells stain positive. Average stain
intensity ranged from 1 to 3 (lowest to highest intensity).
Field location and number were selected randomly at
the discretion of the individual scorer. The product of the
percentage and intensity scores made up the overall im-
munoreactivity score (ranging from 1 to 9). Both scorers
simultaneously reviewed slides with conflicting scores
(scores deviating by more than 1 in either category) (n = 5)
and consensus was reached. After review, total scores were
averaged for statistical analyses.
Table 1 Summary of data for dogs with DFI > 300 and DFI < 100 days, including HES1 immunohistochemistry score
Breed Age at Dx (yrs) Sex Tumor Loc DFI (days) Avg% stain Avg stain intensity Total score
Greyhound 4.4 MC PH 40 1 1 1
Rottweiler 5 MC DF 69 3 3 9
Greyhound 7 MC DF 77 2 1 2
Mix 9 FS T 90 2 1 2
Greyhound 8 FS PT 94 1 2 2
Labrador 10.2 FS DH 95 3 3 9
Mix 8.8 MC DF 97 2 1 2
Golden 10.8 MC PH 97 2 1 2
Mix 7.6 FS DR 307 2 2 4
Greyhound 7.1 MC PH 467 1 1 1
Mix 12.4 MC DR 694 3 3 9
Malamute 10.1 FS DR 734 3 2 6
Labrador 8.7 MC T 787 3 3 9
Golden 8 FS DR 885 3 2 6
DFI disease free interval, Dx diagnosis, MC male castrated, FS female spayed, P proximal, D distal, H humerus, R radius, T tibia, Total Score is product of scores for
% cells staining and staining intensity.
Dailey et al. BMC Veterinary Research 2013, 9:130 Page 5 of 14
http://www.biomedcentral.com/1746-6148/9/130Immunocytochemistry (ICC)
Immunocytochemistry was performed utilizing the same
reagents and a similar protocol to that used for IHC.
Slides were prepared via cytospin and dried overnight.
Prior to the blocking step cells were fixed with 100%
methanol at room temperature for 15 minutes, allowed
to dry, washed in TTBS and incubated in 0.1% TritonX-
100 in TBS for 7–12 minutes. The remainder of the pro-
cedure was identical to that used for IHC, but a higher
concentration of primary antibody (1:250) was used.
Photomicrographs (IHC and ICC) were taken using
the Olympus BX51 Research System Microscope with an
Olympus dp70 Digital Camera System. Minimal add-
itional editing was done in Microsoft ® PowerPoint ® for
Mac 2011.
Gene expression microarray analysis
Total RNA from primary OSA tumor samples from dogs
with DFI < 100 (n = 8) and DFI > 300 (n = 7) was analyzed
on GeneChip Canine 2.0 Genome Arrays (Affymetrix,
Santa Clara, CA) at CSU’s Rocky Mountain Regional
Center for Excellence (RMRCE) Genomics Core per
Affymetrix protocols as described [35]. Normal bone sam-
ples (n = 8) were analyzed using an identical protocol.
Samples used for microarray analysis were a subset of
those used for RT-qPCR (microarray samples were limited
due to array costs). Microarray pre-processing combining
the osteosarcoma samples with the normal bone samples
was conducted using Probe Logarithmic Intensity Error
(PLIER) estimation algorithms with log2 transformations.
Probesets including Notch receptor ligands, effectors, or
targets of either the canonical Notch pathway or HES1
were selected based on literature review, Ingenuity®Systems Pathway analysis, and/or inclusion in The Human
Notch Signaling Pathway RT2 Profiler™ PCR Array
(SAbiosciences) (Additional file 1). CIMminer was used to
generate clustered images of the data from the 75 selected
probesets with unsupervised clustering on both axes and
the following parameters: average linkage, Euclidean dis-
tance, and quantile binning with median centering of the
data. Full microarray data for the DFI groups is available
through NCBI’s Gene Expression Omnibus (GEO) via ac-
cession number GSE24251.Statistics
Statistical analysis of RT-qPCR and immunohistochemis-
try data (not including survival data) was performed
using Prism software (GraphPad Software, La Jolla, CA).
For RT-qPCR data standard curves, dissociation curves
and amplification data was collected on a Stratagene
Mx3000P instrument and analyzed using the Rest2009
software [38]. HES1 RT-qPCR data was also analyzed
using the 2(−ΔΔCt) method [39] with similar results. IHC
scores for the DFI > 300 and DFI < 100 tumors were ana-
lyzed with a 2-tailed Fischer’s exact test after separating
scores into low expression (total score less than 4) and
high expression (total score greater than or equal to 4)
categories. The cut off was based on results of receiver-
operating characteristic (ROC) analysis of immunohisto-
chemical scores for the DFI > 300 and DFI < 100 groups.
Welch t-test in ArrayTrack 3.5.0 with false discovery
rate correction for multiple comparisons (FDR; based on
all array probesets) was used to compare microarray
gene expression data. Significance was defined as p < 0.05
(Welch t-test) or q < 0.05 (FDR).
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using a combination of Prism and SPSS software version
20 for Macintosh (IBM, Armonk, NY). Correlations be-
tween HES1 expression levels and other markers on a
continuous scale were evaluated using linear regression
analysis. A 2-tailed, unpaired t-test was used to evaluate
the association between HES1 expression levels and cat-
egorical markers. The median DFI was estimated using
the Kaplan-Meier method, and comparisons between
groups made using log rank analysis for categorical vari-
ables. For continuous variables, markers were catego-
rized into a low and high group using the median value
as the break point. Multivariable Cox regression analysis
was then performed, utilizing both forward and back-
ward stepwise models. Variables identified with a univar-
iate p-value of <0.1 were included in the multivariate
analysis. For all other tests, p-values of <0.05 were con-
sidered significant.
Results
Gene expression analysis of Notch/HES1-associated genes
groups normal and OSA bone samples, but does not
distinguish DFI groups
To assess the biological relevance of Notch/HES1 signal-
ing in canine osteosarcoma, probesets including Notch
receptor ligands, effectors, or targets of either the ca-
nonical Notch pathway or HES1 were selected from Ca-
nine 2.0 gene array data and analyzed for differential
gene expression as described in materials and methods.
Unbiased cluster analysis of data for the 51 Notch/
HES1-associated genes separated normal bone from tu-
mors, but did not discriminate between the DFI groups
(Figure 1). In total, 30 of 51 (58.8%) Notch/HES1 path-
way associated genes examined were significantly differ-
ent between tumor and normal bone (p < 0.05, q < 0.05);
23/30 (76.7%) had increased expression in tumors. Spe-
cifically, mRNA expression of NOTCH1 and NOTCH2
was elevated in tumor samples compared to normal
bone (p < 0.05, q < 0.05). None of the genes evaluated
had significantly different expression between DFI
groups when corrected for multiple comparisons. HES1
was not included on the Canine 2.0 chip, but HEY1, an-
other Notch target, was also elevated in tumors com-
pared to normal bone (p < 0.05, q < 0.05).
RT-qPCR analysis for NOTCH1, NOTCH2, HEY1 and
HES1 was conducted on the normal bone/matched OSA
and DFI tumor sample sets (Figures 2 and 3). NOTCH1
exhibited decreased expression in the DFI < 100 day
group relative to normal bone (FC down – 1.656,
p < 0.001), with no other significant changes measured.
This result differed from the 1.27 fold upregulation of
NOTCH1 identified in the gene array analysis, however pre-
vious studies have shown that fold-change differences <1.5
are frequently unreliable [40]. Consistent with the arraydata, NOTCH2 exhibited an approximate 4-fold elevation
in expression in both sets of DFI tumors, separately and in
combination, relative to normal bone (p < 0.001). Similarly,
HEY1 expression was elevated in each tumor group by a
fold-change ranging from 6 to 10.2 (p ≤ 0.001). RT-qPCR
analysis of these Notch signaling pathway elements con-
firmed our finding that Notch signaling is elevated in tu-
mors relative to normal bone, but not between tumors in
the two DFI groups.
HES1 mRNA expression in tumors and its prognostic
significance
RT-qPCR was also used to assess HES1 mRNA levels in
OSA tumor and matched normal bone samples. Average
HES1 mRNA expression was elevated 2.57-fold in canine
OSA tumors compared to the matched normal bone
(Figure 3A; p = 0.012); however, this fold change was
highly variable when each OSA tumor was compared
to its matched normal bone sample, with 5 tumors
exhibiting elevated expression compared to normal bone
and 4 tumors having virtually unchanged expression
(Figure 3B, range 1.19-6.17-fold).
We also assessed mRNA levels for HES1 in tumors
taken from dogs with a DFI <100 days or DFI >300 days
following treatment by amputation and chemotherapy.
We found that HES1 expression was elevated 4.608-fold
in the DFI > 300 tumors compared to the DFI < 100
group (Figure 3A; p < 0.001). HES1 expression in the
DFI < 100 group was not different from the normal bone
samples.
Messenger RNA levels of HES1 were measured in ca-
nine and human osteosarcoma cell lines and confirmed
using Western blot analysis using a rabbit monoclonal
anti-human HES1 antibody as described to determine if
HES1 mRNA levels correlated to protein expression,
(Figures 4 and 5, Additional file 3). Comparison of ca-
nine and human amino acid sequence of the HES1 gene
identified 86% homology in the epitope targeted by this
antibody. This was based on the predicted amino acid
sequence of NCBI reference sequence XM_548669.1,
which has been removed as a result of standard genome
annotation processing. No additional canine HES1 rec-
ord is currently available. Western blot analysis of whole
cell OSA cell lysates revealed a 30 kD protein (HES1) as
well as larger non-specific bands (Figure 4A, W). Given
the role of HES1 as a transcriptional regulator, we hy-
pothesized that active HES1 protein would reside in the
nucleus. Western blot analysis of isolated nuclear and
cytoplasmic fractions from both canine and human OSA
cell lines confirmed enrichment of the 30 kD HES-1
protein in the nuclear fraction (Figure 4A, N) while the
non-specific bands were enriched in the cytoplasm frac-
tion (Figure 4A, C). Since equal amounts of total protein






















































Figure 1 Differential expression of Notch/HES1-associated genes in canine osteosarcoma. Unbiased cluster analysis separates normal bone
from tumors, but does not discriminate DFI < 100 day and DFI > 300 day primary tumors groups. An asterisk (*) and a caret (^) denote genes
significantly different between tumor and normal bone (* p < 0.05, ^ q < 0.05). Genes different between DFI groups (p < 0.05) are denoted by (~).
Multiple probesets are present for some genes. LOC486276 = Deltex 1 homolog (DTX1), LOC489891 = LFNG O-fucosylpeptide 3-beta-N-
acetylglucosaminyltransferase/lunatic fringe (LFNG). Colored bar below indicates the intensity scale of log2 transformed expression values.
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were likely the result of concentration of these cytoplasmic
proteins relative to total protein. Experiments using hu-
man OSA cells showed similar results (Additional file 3).
HES1 mRNA and protein expression varied between
cell lines in both canine and human OSA cells (Figure 5).For human cell lines mRNA expression was similar to that
previously published [24,25]. In general, HES1 mRNA ex-
pression was increased in canine cell lines relative to nor-
mal canine bone tissue (Figure 5A) and in human OSA
cell lines relative to human osteoblasts (Figure 5C).
Western blot analysis showed a characteristic band at




















































































































Figure 2 Expression of NOTCH1, NOTCH2 and HEY1 mRNA in canine normal bone and osteosarcoma (RT-qPCR). NOTCH1, NOTCH2, and
HEY1 mRNA expressed as 2(−ΔCT) normalized to HPRT1 is shown for normal bone (n = 9), matched tumors (n = 9), tumors from dogs with DFI >
300 days, tumors from dogs with DFI < 100 days, and combined DFI group tumors. Comparisons of each tumor group relative to normal bone
and DFI < 100 relative to DFI > 300 day groups were analyzed with REST 2009 software and significant fold changes are indicated by brackets on
the graph. Values in blue indicate the reduced fold-change expression in DFI < 100 compared to normal bone. Bars represent mean ± SEM.
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(Figure 5B and 5D). Interestingly, the metastatic subline
of MG63 cells, MG63.2, exhibited elevated levels of
mRNA compared to the MG63 line, but protein expres-
sion was not significantly different between the two

















































Figure 3 Expression of HES1 mRNA in canine normal bone and osteo
to HPRT1 in normal bone (n = 9), matched tumors (n = 9), tumors from dog
(n = 10), and combined DFI group tumors. Comparisons of each tumor gro
groups were analyzed with REST 2009 software and significant fold change
reduced fold-change in DFI < 100 relative to DFI > 300 group. (B) Fold chan
method between each canine tumor and its matched normal bone sampleWe validated immunoreactivity using FFPE human
placenta and found positive strong nuclear and cytoplas-
mic staining of placental macrophages (Hafbauer cells),
moderate nuclear +/− cytoplasmic staining of stromal
cells and light nuclear staining of endothelial cells con-



































sarcoma (RT-qPCR). (A) HES1 mRNA expressed as 2(−ΔCT) normalized
s with DFI > 300 days (n = 10), tumors from dogs with DFI < 100 days
up relative to normal bone and DFI < 100 relative to DFI > 300 day
s are indicated by brackets on the graph. Values in blue indicate
ge in expression calculated using the comparative Ct (2(−ΔΔCt))
(normalized to HPRT1). Bars represent mean ± SEM.
Abrams Gracie 










Figure 4 Western blot and immunocytochemistry (ICC) results
assessing HES1 expression in canine osteosarcoma cells. (A)
Western blot analysis of whole cell (W), nuclear (N) and cytoplasmic
(C) fractions of canine osteosarcoma Abrams and Gracie cell lines. A
30 kDa band (HES1) is present in whole cell and enriched in
extracted nuclear lysates. Larger non-specific bands are enriched in
the cytoplasmic fractions. Equal amounts of total protein were
loaded in each lane. (B) ICC shows nuclear staining for HES1 in
canine OSA cells (Gracie). Panel on the right is the secondary-only
negative control. Photomicrographs were taken at 20× and 100×
(oil, inset) magnification; haemotoxylin counterstain.
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revealed positive punctate to diffuse intranuclear stain-
ing of pancreatic cells, endothelial cells and subsets of
pulmonary epithelial cells as described in human lite-
rature [42-44] (see Additional file 5). Addition of a
blocking peptide specific for the epitope targeted by our
antibody eliminated all staining (data not shown). Im-
munocytochemistry of canine OSA cells (Gracie) showed
diffuse nuclear staining consistent with the specific
30 kDa protein identified in the nuclear lysate by west-
ern analysis (Figure 4B).
Increased immunohistochemical HES1 staining is
associated with increased disease free interval
Once we established that the RabMAb anti-human
HES1 antibody provided specific targeting of HES1 pro-
tein in human cultured cells and FFPE tissues with good
cross-reactivity in canine samples, we performed immu-
nohistochemistry using canine primary OSA samples. Of
the 20 tumor samples from the canine DFI > 300 and
DFI < 100 tumor groups, 14 were scored as described in
the methods (Figure 6). For six samples, IHC was notpossible due to loss of tissue during processing or poor
quality/quantity of staining/tissue present. All OSA sam-
ples evaluated with immunohistochemistry had variable
positive staining for HES1 both across tumors and
within tumors. The staining pattern of tumor cells was
predominantly nuclear with diffuse cytoplasmic staining
less common. The median HES1 reactivity score was 3
(range, 1 to 9). Of the 6 tumors from dogs with DFI >
300 days, 83.3% (n = 5) had a score of greater than 3,
compared to only 25.0% (n = 2) of the 8 tumors from
dogs with DFI < 100 days (Table 1). Consistent with our
RT-qPCR results, average HES1 immunohistochemical
staining was lower in tumors from dogs with DFI <
100 days, but because of low power did not reach statis-
tical significance (Additional file 6).
To further assess the utility of HES1 protein expres-
sion as a prognostic biomarker, we performed IHC on
61 primary canine OSA tissues from a subset of dogs in
a previously reported prospective clinical trial [33].
Demographic information for this patient population is
supplied in Additional file 7. IHC scores were assigned
as described in materials and methods. HES1 was
expressed in all tumors with a median HES1 immunore-
activity score of 4 in this population (range, 1 to 9). The
overall median DFI was 168 (range 43 to 1,393+ days).
The median DFI in dogs with a high HES1 immuno-
reactivity score (≥ 4) was 258 days compared to 155 days
in dogs with a low HES1 immunoreactivity score (< 4)
(p = 0.0023; Figure 7). Univariate analysis identified
HES1, bone-specific alkaline phosphatase (BALP) activ-
ity, histologic grade, percent necrosis and mitotic index
as potential predictors of DFI (Table 2, p < 0.1). Upon
multivariate analysis, HES1, percent necrosis and mitotic
index retained statistical significance (p = 0.029, 0.002
and 0.005 respectively; Table 2) as independent predic-
tors of DFI. In summary, consistent with our prior RT-
qPCR analysis, increased HES1 expression was identified
as an independent prognostic biomarker for increased
disease free survival in 61 canine OSAs treated by ampu-
tation and chemotherapy.
Discussion
Expression of HES1 mRNA is frequently utilized as an in-
dicator of Notch activity and Notch/HES1 activation has
been implicated in a variety of human cancers with onco-
genic activity in some tumor types and tumor suppressor
activity in others [17-20,24-27]. The goals of this study
were to evaluate expression of Notch receptors and signal-
ing mediators, HES1 and HEY1, in canine OSA samples
from dogs with DFI > 300 days and DFI < 100 days as well
as samples of matched OSA and normal bone to explore
associations with OSA progression and patient outcome.
Gene array analysis focusing on 51 Notch/HES1 associated





































































Figure 5 Expression of HES1 mRNA and protein in human osteosarcoma cell lines. HES1 mRNA in canine OSA cell lines and normal canine
bone tissue (NB) expressed as 2(−ΔCT) normalized to HPRT1 (A). HES1 mRNA in human OSA cell lines and normal human osteoblasts expressed as
2(−ΔCT) normalized to the geometric mean of RBS15, GAPDH, 18SrRNA, and HPRT1 (C). Data are graphed as mean ± SEM, *** P < 0.001, ** P < 0.01,
Two-way ANOVA with Dunnett’s Multiple Comparison Test. (B and D) Western blot shows characteristic distinct HES1 band at 30 kDa. Blot was
stripped and re-probed with an antibody against α-tubulin to serve as a protein loading control.
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firmed a statistically significant elevation of NOTCH2,
HEY1, and HES1 mRNA expression in OSA when com-
pared with normal bone. Interestingly, we did not find ele-
vated HES1 expression in the most aggressive OSA when
comparing good and poor responders, but instead identi-
fied a statistically significant association between high
HES1 mRNA and protein expression and longer DFI fol-
lowing standard treatment. Further, the gene array analysis
of Notch/HES1 associated genes and RT-qPCR analysis of
NOTCH1, NOTCH2 and HEY1 showed no significant dif-
ferences in expression between the DFI groups. Overall,
our findings indicate that alterations in Notch signaling
occur during the development of canine OSA, but mecha-
nisms that do not alter HES1 expression may drive the
most aggressive tumors.
The oncogenic role of Notch signaling in OSA in
humans is supported by previous studies [24-26]; how-
ever, the specific role of HES1 is less clear. A common
finding regarding HES1 expression between these previ-
ous studies and ours is the variability of expression
within human and canine OSA cells and tumors (please
note for references 24 and 28, that data from experi-
ments done using the OS187 or COL cell lines should
be viewed with caution due to a recent disclosure that
these cells are not OSA cells) [24-26,28]. For example,HES1 mRNA expression in tumors relative to normal
bone was elevated in 5 of 9 canine tumors relative to
matched normal bone samples in our study (Figure 3B)
and 6 of 10 human tumors in the Tanaka study [25].
There is also disagreement among studies as to which
Notch receptors and target genes are functionally signifi-
cant in OSA. Zhang et al. provided evidence that in-
creased Notch1 activity and Notch1-induced expression
of HES1 specifically are associated with invasion and
metastasis in two OSA cell lines, the low HES1 express-
ing SAOS2 parental line and the metastatic, high HES1
expressing LM7 sub-line [24]. Inhibition of Notch sig-
naling by a gamma-secretase inhibitor suppressed LM7
OSA cell invasion, but had no effect on proliferation or
tumorigenesis; whereas induced expression of intracellu-
lar cleaved Notch1 (ICN1) or HES1 in the SAOS2 line
increased invasiveness. Tanaka et al. identified elevations
of NOTCH2 and HEY1 mRNA in human OSA biopsy
specimens relative to normal bone, but NOTCH1 and
HES1 mRNA expression was not consistently elevated.
In the same study, treatment of OSA cells and tumors
grown in nude mice with a gamma-secretase inhibitor
reduced proliferation through a G1 block [25]. Differing
results in these two studies may be due to different sam-
ples studied (tumor vs. cells) and/or the use of different
gamma-secretase inhibitors. Our RT-qPCR data suggests
A B
C D
Figure 6 Immunohistochemical analysis of nuclear HES1
protein expression in canine osteosarcoma. Examples of low (A
and B, score 2) and high (C, score 6) nuclear HES1 expression in
canine osteosarcomas (D is a negative control treated only with
secondary antibody). Panel B shows example of a field from a low
scoring tumor (based on nuclear staining) that includes scattered
strong cytoplasmic staining (arrows). All photomicrographs were
taken at 40× magnification; haematoxylin counterstain.
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Figure 7 High HES1 immunoreactivity score correlates with
lower histologic grade and improved outcome in canine
osteosarcoma. Kaplan-Meier plot of disease free interval based on
HES1 immunoreactivity score. Dogs with high HES1 scoring tumors
(score ≥ 4, n = 28) had a statistically significantly longer disease free
interval than dogs with low HES1 scoring tumors (score < 4, n = 33)
(p = 0.0023, Log Rank test).
Table 2 Results of univariate/multivariate analysis of
factors associated with clinical outcome
Univariate analysis
Median DFI (d) HR P 95% CI
HES1 Score <4 155 0.388 0.0023 0.211-0.712
≥4 258
BALP <36 273.5 1.871 0.0377 1.036-3.378
≥36 157
Necrosis% <20% 239 1.799 0.098 0.897-3.609
≥20% 168
Mitotic Index <54 258 3.234 0.0163 1.241-8.428
≥54 153
Grade 1 or 2 308 15.43 <0.0001 4.243-56.07
3 75
Multivariate analysis
HR P 95% CI
HES1 Score 0.775 0.029 0.616-0.975
Necrosis% 1.032 0.002 1.012-1.053
Mitotic Index 1.033 0.005 1.01-1.057
DFI disease free interval, BALP bone-specific alkaline phosphatase.
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Notch signaling in canine OSA as well. Interestingly,
Zhang et al. observed both elevated HES1 mRNA ex-
pression [24] and elevated HES1 protein expression [28]
in the LM7 metastatic sub-line relative to the SAOS2
parent line. We also observed an increase in HES1
mRNA expression in the MG63.2 metastatic sub-line
relative to the MG63 parent line. However, western blot
analysis identified similar levels of HES1 protein in
the MG63 and MG63.2 lines suggesting that post-
transcriptional regulation may be important.
Studies exploring the relationship between HES1 ex-
pression and patient outcome in OSA are limited. Our
RT-qPCR results (n = 20) revealed significantly increased
HES1 mRNA expression in canine OSA from dogs with
a longer DFI compared to those with a short DFI. This
relationship was confirmed by immunohistochemical
examination of HES1 protein in a larger dataset (n = 61).
These results conflict with those of Hughes who
conducted a RT-qPCR study using tissue from 16primary OSAs that suggested lower HES1 mRNA ex-
pression may be associated with a better prognosis [27].
Discrepancy from our results may be due to differing
sample sizes, different measurements of outcome and
different outcome groupings. Despite evidence of strong
molecular similarities of canine and human OSA and
high conservation of Notch/HES1 between species, there
is also the possibility that canine tumors may exhibit dif-
ferent characteristics than their human counterparts.
Dailey et al. BMC Veterinary Research 2013, 9:130 Page 12 of 14
http://www.biomedcentral.com/1746-6148/9/130Until similar studies to evaluate nuclear immunoreactiv-
ity as a measure of protein expression are carried out in
human tumors, no firm conclusions regarding possible
differences in canine and human OSA with respect to
HES1 expression can be made.
Previous studies examining HES1 expression in other
cancers or during development provide candidate mech-
anisms for reduced HES1 expression in the presence of
elevated Notch signaling: uncoupling of HES1 from
Notch signaling, cell cycle regulation of HES1 expres-
sion, and post-transcriptional regulation. HES1 expres-
sion has been reported to be uncoupled from Notch
signaling in Ewing’s sarcoma [15] and stimulation of
HES1 transcription by sonic hedgehog (Shh) pathway
occurs in mesodermal and neural stem cells [6 – 8].
Using RT-qPCR analysis, we identified significantly de-
creased SMO mRNA expression (p < 0.05) in the DFI <
100 tumors compared to the DFI > 300 tumors [32]
suggesting that reduced HES1 expression in aggressive
canine OSA might reflect a loss of Shh signaling. HES1
expression oscillations are both observed and necessary
for cell cycle progression during neuronal development
[45]; aggressive OSA tumor cells may utilize HES1 oscil-
latory patterns to manipulate the cell cycle and optimize
their ability to metastasize and/or resist chemotherapy.
Finally, several miRNAs have been shown to regulate
HES1 (miR-124 and miR-23b) [46,47] and may contrib-
ute to altered HES1 expression in OSA cells and tumors.
In addition, HES1 protein may exhibit specific func-
tions depending on its phosphorylation status and bind-
ing partners. Kannan et. al. found that interactions with
HES1 stimulates PARP1 activation and cleavage, ultim-
ately resulting in apoptosis in B-ALL (overall a tumor
suppressor role for HES1) [20]. Further, in neuronal de-
velopment, Ju et al. showed that HES1 interactions with
phosphorylated PARP1 released HES1 from the HES1/
groucho/TLE repressor complex and, upon HES1 phos-
phorylation, led to association with a co-activator com-
plex, changing the role of HES1 from a transcriptional
repressor to a transcriptional activator [48]. In bone de-
velopment, via inhibition of RUNX2, Notch activity
maintains a population of committed osteoblast precur-
sors [49,50]. Interestingly, several studies also show that
HES1 binding stabilizes and activates RUNX2 protein;
thus, HES1 has been shown to both inhibit and enhance
the activity of RUNX2 [49,51]. Additional studies explor-
ing the phosphorylation status and binding partners of
HES1 may provide a better understanding of these inter-
actions in OSA.
Conclusions
The results of the current study support the association
of Notch pathway activation with the proliferative re-
sponse of OSA. However, reduced HES1 expression inthe most aggressive tumors despite the elevated expres-
sion of other Notch signaling effectors and targets indi-
cates that HES1 is not an ideal sole surrogate marker of
Notch signaling. Further, these findings suggest that add-
itional mechanisms beyond Notch signaling may con-
tribute to the aggressive phenotype of these tumors.
Studies to define the role of Notch signaling in OSAs is
warranted as inhibitors for this and other developmental
pathways that impinge on HES1 are currently in clinical
trials for the treatment of a variety of human cancers
(summarized in Sang et al.) [52]. Research in this area
may reveal important regulatory mechanisms contribut-
ing to metastasis and therapeutic resistance in both
canine and human OSA. While we found that HES1 ex-
pression was not consistently linked to Notch signaling
in canine OSA, our study has determined that reduced
HES1 expression serves as an independent prognostic
biomarker.
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Additional file 1: Affymetrix Canine 2.0 microarray data processed
with PLIER algorithm. Selected Notch signaling pathway genes from
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published [35] and unpublished data (normal bone).
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primer pairs used in RT-qPCR experiments.
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nuclear and cytosolic fractions for HES1. A distinct band at 30 kDa is
present in both MG63.2 and U2OS human OSA whole cell (W) and is
enriched in nuclear extract (N) lysates. Larger non-specific bands
predominate in the cytoplasmic fraction (C). Equal amounts of total
protein were loaded in each lane.
Additional file 4: HES1 protein expression is not significantly
different between MG63 and MG63.2 cell lines. HES1 band intensity
normalized to α-tubulin loading control. Bars represent mean +/−
standard deviation from four independent experiments. Standard
unpaired 2-tailed t-test was used to compare mean HES1 band intensity
ratios for MG63 and MG63.2 Western blot.
Additional file 5: HES1 immunohistochemistry of control canine
tissues. Variably intense nuclear staining is present in bronchiolar
epithelial cells (A) and in both exocrine and endocrine (islets cells, blue
circle) pancreatic cells (C). B and D are the negative controls. All
photomicrographs were taken at 40× magnification; haematoxylin
counterstain.
Additional file 6: HES1 immunoreactivity in canine osteosarcomas
from DFI < 100 and >300 groups. Immunoreactivity scores of nuclear
HES1 protein expression in tumor sections from DFI < 100 day (filled
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line and error bars are mean ± SEM (p = 0.1026).
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